Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/150433
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Madrid, Lola | - |
dc.contributor.author | Bassat Orellana, Quique | - |
dc.date.accessioned | 2020-02-17T14:13:07Z | - |
dc.date.available | 2020-02-17T14:13:07Z | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 2214-109X | - |
dc.identifier.uri | http://hdl.handle.net/2445/150433 | - |
dc.description.abstract | A decade ago, the astonishing and unexpected results of a trachoma trial in Ethiopia1 hinted at the exciting potential of mass azithromycin distribution to significantly reduce all-cause mortality in children by approximately 50%. In 2018, the Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) multi-country study,2, 3 designed to investigate the effect of mass biannual azithromycin distribution on all-cause mortality in children aged 1–59 months in sub-Saharan African communities, corroborated these results—although with more modest and credible findings than the trachoma trial.1 The greatest reduction in all-cause mortality was observed in Niger, the site with the highest baseline mortality, where biannual mass distribution of azithromycin to children aged 1–59 months decreased all-cause mortality by 18% compared with placebo. | - |
dc.format.extent | 2 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/10.1016/S2214-109X(19)30558-3 | - |
dc.relation.ispartof | Lancet Global Health, 2020, vol. 8, num. 2, p. e169-e170 | - |
dc.relation.uri | http://dx.doi.org/10.1016/S2214-109X(19)30558-3 | - |
dc.rights | cc by-nc-nd (c) Madrid et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | - |
dc.source | Articles publicats en revistes (ISGlobal) | - |
dc.subject.classification | Tracoma | - |
dc.subject.classification | Mortalitat infantil | - |
dc.subject.other | Trachoma | - |
dc.subject.other | Infant mortality | - |
dc.title | Azithromycin for child survival: digging without getting too dirty into the differential effect on cause-specific mortality | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2020-02-14T19:01:26Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31981547 | - |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
MadridL_LancetGlobHeal_2020_Comment.pdf | 38.91 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License